Renal sympathetic denervation in hypertension

Current Opinion in Nephrology and Hypertension

Volumn 20, Issue 6, 2011, Pages 647-653

  Doumas, Michael ^a   Faselis, Charles ^a   Papademetriou, Vasilios ^b  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

hypertension treatment; renal sympathetic denervation; resistant hypertension; sympathetic nervous system

Indexed keywords

ALDOSTERONE; BETA 1 ADRENERGIC RECEPTOR; CREATININE; CYSTATIN C; DIURETIC AGENT; GLUCOSE; GUANETHIDINE; INSULIN; NORADRENALIN; SPIRONOLACTONE;

ADRENERGIC SYSTEM; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CATHETER ABLATION; CHEMICAL SYMPATHECTOMY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE HOMEOSTASIS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY BLOOD FLOW; KIDNEY DENERVATION; MINIMALLY INVASIVE SURGERY; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PATIENT SAFETY; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RENAL ARTERY; RENAL SYMPATHETIC NERVE ABLATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; REVIEW; SYMPATHECTOMY; SYMPATHETIC FUNCTION; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; VASCULAR ACCESS;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CATHETER ABLATION; DRUG RESISTANCE; GLUCOSE; HOMEOSTASIS; HUMANS; HYPERTENSION; INSULIN RESISTANCE; KIDNEY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SYMPATHECTOMY;

EID: 80054745984     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32834b620c     Document Type: Review

References (23)

1. Sarafidis PA, Bakris GL Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008; 52:1749-1757.
2. Faselis C, Doumas M, Papademetriou V. Common secondary causes of resistant hypertension and rationale for treatment. Int J Hypertens 2011; 2011:236239.
3. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation and treatment. Hypertension 2008; 117:510-526.
4. Doumas M, Papademetriou V, Douma S, et al. Benefits from treatment and control of patients with resistant hypertension. Int J Hypertens 2010; 2011:318549.
5. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57:1076-1080.
6. de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57:898-902.
7. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol 2010; 298:R245-R253.
8. Campese VM, Ku E, Park J. Sympathetic renal innervation and resistant hypertension. Int J Hypertens 2011; 2011:81 4354.
9. Doumas M, Faselis C, Papademetriou V. Renal sympathetic denervation and systemic hypertension. Am J Cardiol 2010; 105:570-576.
10. Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361:932-934.
11. Schlaich MP, Straznicky N, Grima M, et al. Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens 2011; 29:991-996.
12. Voskuil M, Verloop WL, Blankestijn PJ, et al. Percutaneous renal denervation for the treatment of resistant essential hypertension: the first Dutch experience. Neth Heart J 2011; 19:319-323.
13. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373:1275-1281.
14. Doumas M, Douma S. Interventional management of resistant hypertension. Lancet 2009; 373:1228-1230.
15. Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376:1903-1909.
16. Bunte MC. Renal sympathetic denervation for refractory hypertension. Lancet 2011; 377:1074.
17. Esler M. Renal sympathetic denervation for refractory hypertension. Lancet 2011; 377:1074-1075.
18. Doumas M, Douma S. Renal sympathetic denervation: the jury is still out. Lancet 2010; 376:1878-1880.
19. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57:911-917.
20. Lembo G, Grassi G. A lesson from polycystic ovarian syndrome: untangling the role of renal sympathetic nervous system on hypertension and insulin resistance. J Hypertens 2011; 29:836-837.
21. Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011; 123:1940-1946.
22. Sverrisdottir YB, Mogren T, Kataoka J, et al. Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth? Am J Physiol Endocrinol Metab 2008; 294:E576-E581. (Pubitemid 351355228)
23. Papademetriou V, Doumas M, Tsioufis K. Renal sympathetic denervation for the treatment of difficult-to-control or resistant hypertension. Int J Hypertens 2011; 196518.